IKS applies laboratory expertise to motorcycling
Sets up racing team and uses XiltriX to monitor racing performance of rider Mervyn Verploegen
According to IKS md Stephen Tierney, this is not just the usual sponsorship arrangement: IKS will be applying the expertise accumulated in more than 20 years of laboratory monitoring to improve racing performance.
‘We’re delighted to be able to help this young talent advance his sporting career and to support his family, who are very much involved,’ he said. ‘Unusually in such situations, though, we can also contribute technically by applying the technology employed in our XiltriX laboratory monitoring systems to measuring parameters such as tyre temperature and pressure that have a significant impact on racing performance.’
He added: ‘Motor racing is pure adrenaline, but control is vital: our traditional markets are rather more conservative and sometimes slow moving, but control is every bit as important. We like to think that being involved in two such different environments will help develop the progressive and innovative philosophy that will drive our company forward.’
IKS International, based in Rosmalen, near 's-Hertogenbosch, supplies advanced products and services to clinical, biotechnology, pharmaceutical and microbiology laboratories worldwide.
You may also like
Manufacturing
Buckland Group launches Quvara Medical after acquiring Becton Dickinson’s Swindon site to boost UK-EU medical manufacturing
The acquisition establishes Quvara Medical as a new UK- and EU-based CMO offering GMP- and ISO-certified, high-volume manufacturing services to pharma and medtech clients
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
Rentschler Biopharma and Coriolis Pharma partner to deliver integrated biopharma development and manufacturing solutions
The German-based CDMO and CRDO will offer unified formulation-to-manufacturing services to accelerate biologics development. The collaboration aims to cut complexity, timelines and risk for global biopharma clients